---
title: "Viatris Inc. Stock Rises Friday, Still Underperforms Market"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275178985.md"
description: "Shares of Viatris Inc. (VTRS) rose 1.67% to $14.58 on Friday, although the stock still underperformed compared to the broader market, with the S&P 500 and Dow Jones Industrial Average increasing by 1.97% and 2.47%, respectively. Viatris reached a new 52-week high, surpassing its previous peak of $14.50 from February 4th. Trading volume was 8.5 million, slightly below the 50-day average of 8.5 million."
datetime: "2026-02-06T22:11:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275178985.md)
  - [en](https://longbridge.com/en/news/275178985.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275178985.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275178985.md) | [繁體中文](https://longbridge.com/zh-HK/news/275178985.md)


# Viatris Inc. Stock Rises Friday, Still Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Viatris Inc. (VTRS) advanced 1.67% to $14.58 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 1.97% to 6,932.30 and the Dow Jones Industrial Average rising 2.47% to 50,115.67.

Viatris Inc. hit a new 52-week high, surpassing its previous peak of $14.50, which the company reached on February 4th.

Trading volume (8.5 M) remained 2,252 below its 50-day average volume of 8.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled February 6, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

02-06-26 1711ET

### 相关股票

- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [Viatris (VTRS.US)](https://longbridge.com/zh-CN/quote/VTRS.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)

## 相关资讯与研究

- [Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research](https://longbridge.com/zh-CN/news/278908205.md)
- [A Look At Viatris (VTRS) Valuation After Earnings, 2026 Guidance And MR-141 FDA Review](https://longbridge.com/zh-CN/news/277640565.md)
- [Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs](https://longbridge.com/zh-CN/news/278102320.md)
- [SAB Reports C-Peptide Preservation Signals in Type 1 Diabetes Trial](https://longbridge.com/zh-CN/news/278591939.md)
- [Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market](https://longbridge.com/zh-CN/news/278917368.md)